| Species |
Human |
| Protein Construction |
TFPI (Asp29-Lys282)_x000D_
Accession # P10646-1 |
His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its ability to inhibit trypsin cleavage of a fluorogenic peptide substrate, the IC50 value is < 0.75 nM. Test result meets the standard |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
32.1 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 40-50 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Oestrogens influence the pathophysiology and development of hormone-sensitive cancers, such as breast cancer. Tissue factor pathway inhibitor (TFPI) is a serine protease inhibitor of the extrinsic coagulation pathway and has recently been associated with breast cancer cell development. |
| Synonyms |
LACI; TFPI1; EPI; TFI; convertin; TFPI |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
